U.S. markets close in 58 minutes
  • S&P 500

    3,773.70
    -46.02 (-1.20%)
     
  • Dow 30

    30,928.53
    -341.56 (-1.09%)
     
  • Nasdaq

    12,763.69
    -234.06 (-1.80%)
     
  • Russell 2000

    2,145.13
    -62.67 (-2.84%)
     
  • Crude Oil

    64.05
    +2.77 (+4.52%)
     
  • Gold

    1,696.00
    -19.80 (-1.15%)
     
  • Silver

    25.39
    -1.00 (-3.78%)
     
  • EUR/USD

    1.1972
    -0.0095 (-0.79%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • GBP/USD

    1.3890
    -0.0062 (-0.45%)
     
  • USD/JPY

    107.9270
    +0.9250 (+0.86%)
     
  • BTC-USD

    48,148.69
    -3,087.15 (-6.03%)
     
  • CMC Crypto 200

    964.90
    -22.31 (-2.26%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Novavax signs deal with SK Bioscience for 40 mln vaccine doses for S. Korea

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Feb 15 (Reuters) - U.S. drug developer Novavax Incsaid on Monday it has signed a license agreement with SouthKorea manufacturer SK Bioscience to produce 40 million doses ofits COVID-19 vaccine for South Korea.

"Concurrently, SK Bioscience has finalized an advancepurchase agreement with the Korean government to supply 40million doses of NVX-CoV2373 to the Republic of Korea beginningin 2021", Novavax said in a statement https://bit.ly/37eMKB2.

(Reporting by Kanishka Singh in Bengaluru; Editing by KimCoghill)